PDA

View Full Version : Merck KGaA suffers major blow as MS drug fails in late-stage trials - Reuters


news
12-06-2023, 09:00 AM
Merck KGaA suffers major blow as MS drug fails in late-stage trials (https://news.google.com/rss/articles/CBMid2h0dHBzOi8vd3d3LnJldXRlcnMuY29tL2J1c2luZXNzL2 hlYWx0aGNhcmUtcGhhcm1hY2V1dGljYWxzL21lcmNrLWtnYWEt c2F5cy1tcy1kcnVnLWZhaWxzLWxhdGUtc3RhZ2UtdHJpYWxzLT IwMjMtMTItMDUv0gEA?oc=5) Reuters
Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis (https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9tZX Jjay1rZ2FhLWRhcm1zdGFkdC1nZXJtYW55LXByb3ZpZGVzLTIy NDkwMDMyNS5odG1s0gEA?oc=5) Yahoo Finance
Merck MS Drug Fails to Meet Target of Late-Stage Trials (https://news.google.com/rss/articles/CBMiYmh0dHBzOi8vd3d3Lndzai5jb20vaGVhbHRoL3BoYXJtYS 9tZXJjay1tcy1kcnVnLWZhaWxzLXRvLW1lZXQtdGFyZ2V0LW9m LWxhdGUtc3RhZ2UtdHJpYWxzLTNiYjgyMjVk0gEA?oc=5) The Wall Street Journal
Evobrutinib Phase III | Merck (https://news.google.com/rss/articles/CBMiPWh0dHBzOi8vd3d3Lm1lcmNrZ3JvdXAuY29tL2VuL25ld3 MvZXZvYnJ1dGluaWItcGhhc2UtbGxsLmh0bWzSAQA?oc=5) Merck KGaA

More... (https://news.google.com/rss/articles/CBMid2h0dHBzOi8vd3d3LnJldXRlcnMuY29tL2J1c2luZXNzL2 hlYWx0aGNhcmUtcGhhcm1hY2V1dGljYWxzL21lcmNrLWtnYWEt c2F5cy1tcy1kcnVnLWZhaWxzLWxhdGUtc3RhZ2UtdHJpYWxzLT IwMjMtMTItMDUv0gEA?oc=5)